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Background-—Major advances have been made in the treatment of ST-elevation myocardial infarction (STEMI) in outpatients. In
contrast, little is known about outcomes in STEMI that occur in patients hospitalized for a noncardiac condition.
Methods and Results-—This was a retrospective, single-center study of inpatient STEMIs from January 1, 2007, to July 31, 2011.
Forty-eight cases were confirmed to be inpatient STEMIs of a total of 139 410 adult discharges. These patients were older and
more often female and had higher rates of chronic kidney disease and prior cerebrovascular events compared with 227 patients
with outpatient STEMIs treated during the same period. Onset of inpatient STEMI was heralded most frequently by a change in
clinical status (60%) and less commonly by patient complaints (33%) or changes on telemetry. Coronary angiography and
percutaneous coronary intervention were performed in 71% and 56% of patients, respectively. The median time to obtain ECG (41
[10, 600] versus 5 [2, 10] minutes; P<0.001), ECG to angiography time (91 [26, 209] versus 35 [25, 46] minutes; P<0.001) and
ECG to first device activation (FDA) (129 [65, 25] versus 60 [47, 76] minutes; P<0.001) were longer for inpatient versus outpatient
STEMI. Survival to discharge was lower for inpatient STEMI (60% versus 96%; P<0.001), and this difference persisted after adjusting
for potential confounders.
Conclusions-—Patients who develop a STEMI while hospitalized for a noncardiac condition are older and more often female, have
more comorbidities, have longer ECG-to-FDA times, and are less likely to survive than patients with an outpatient STEMI. ( J Am
Heart Assoc. 2013;2:e000004 doi: 10.1161/JAHA.113.000004)
Key Words: myocardial infarction • reperfusion • ST elevation MI • inpatient STEMI
R apid reperfusion with early percutaneous coronaryintervention (PCI) is the standard of care for patients
with ST-elevation myocardial infarction (STEMI) who present
to a hospital with interventional cardiology capabilities.
Recognition of the importance of rapid reperfusion has led
to significant improvement in door-to-balloon times in the last
5 years (from a median of 96 minutes in 2005 to 64 minutes
in 2010), which correlates with an improvement in overall
outcomes of STEMI patients.1 Research and nationwide
initiatives on STEMI care have targeted patients who have
onset of STEMI while outside the hospital. Much less is known
about clinical presentation, sources of delay in diagnosis and
treatment, and outcomes in patients who develop STEMIs
while hospitalized for a noncardiac condition. Patients in the
hospital for treatment of active medical or surgical conditions
are susceptible to developing STEMIs, but we know surpris-
ingly little about optimal care in this setting.
Methods
This was a single-center retrospective study performed at the
University of North Carolina Hospitals (UNC), an academic
tertiary health care facility. After approval by the institutional
review board, we searched the hospital discharge database
from January 1, 2007, to July 31, 2011, for patients with a
diagnosis code of “acute myocardial infarction, not present on
admission” using ICD-9 codes 410.00 to 410.92. For
comparison, we identified all outpatients with STEMI who
presented directly to UNC during this period using a STEMI
database maintained by the hospital (patients who were
transferred from another health care facility were excluded).
History of cerebrovascular accident or transient ischemia
attack was obtained from the medical record. Sleep apnea,
hypertension, diabetes mellitus, and/or chronic obstructive
pulmonary disease (COPD) were considered present if the
patient was receiving treatment. Known coronary artery
disease was present if the patient had prior angiographic
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evidence of >70% stenosis in a major epicardial coronary
artery or branch, history of coronary revascularization, or prior
MI. Chronic kidney disease (CKD) was considered present as
a binary variable if the patient had been diagnosed with stage
3, 4, or 5 CKD.
Continuous variables are presented as meanstandard
deviation if normally distributed and median (25%, 75%) if
nonnormally distributed. Differences in continuous variables
were compared using the Student t test for normally
distributed continuous variables and the Wilcoxon rank sum
test for nonnormally distributed continuous variables. Cate-
gorical variables were compared using the v2 test or a Fisher’s
exact test when appropriate. Data are presented in graphical
form using box-and-whisker plots, with boxes representing
medians with 25th and 75th quartiles, whiskers representing
10th and 90th percentiles, and dots representing data points
that fall outside the 10th and 90th percentiles.
To correct for potential confounding of survival, models
were created with the following covariates: age, sex, hyper-
tension, diabetes mellitus, hyperlipidemia, coronary artery
disease, cerebrovascular accidents, CKD, chronic obstructive
pulmonary disease, and outpatient medications. The model
considered use of aspirin, clopidogrel, beta-blockers, angio-
tensin-converting enzyme inhibitors or angiotensin receptor
blockers, and statins. Statistically significant covariates were
identified by partial F test for continuous covariates and by
likelihood ratio tests for dichotomous covariates. The final
models present adjusted percentages of survival based on the
beta estimates from a multiple logistic regression. Differences
were considered significant at P<0.05.
Results
Two hundred and seventy-three discharges were coded with
a diagnosis of “acute myocardial infarction not present on
admission” of a total of 139 410 adult discharges. Of
these, 48 cases were confirmed to be STEMI on the basis
of independent reviews by 2 experienced cardiologists
following established criteria.2,3 Twenty-seven inpatient
STEMIs developed at various postoperative stages, whereas
21 patients were in the hospital being treated for a
nonsurgical condition. In comparison with 227 patients with
outpatient STEMIs treated at our hospital during the same
period, inpatient STEMI patients were older (68 [59, 79]
versus 60 [50, 70] years) and more often female, had
higher rates of CKD and prior cerebrovascular events, and
were more likely to be taking aspirin, dual antiplatelet
therapy, a beta-blocker, and a statin drug prior to admission
(Table 1). There was a trend toward a higher rate of known
coronary artery disease in inpatient STEMIs (42% versus
27%; P=0.06).
The event that triggered the performance of the index ECG
for inpatient STEMI was most often a change in clinical status
(ie, altered mental status, hypotension, and respiratory
distress; n=29, 60.4%). Less frequently, an ECG was obtained
in response to patient complaints (ie, chest pain, dyspnea,
and/or palpitations; n=16, 33%) or changes on telemetry (ie,
tachycardia, ST-segment deviation; n=3, 6.6%). Nine of the
cases were identified by an ECG obtained after the discovery
of elevated cardiac biomarkers.
The time between onset of the ischemic event and the
performance of the index ECG varied dramatically, from a few
minutes to more than 48 hours (Figure 1). The median time to
obtain an ECG was 41 (10, 660) minutes in the 44 patients in






Age (y) 68 (59, 79) 60 (50, 70) <0.001
Sex (% female) 50% 33% 0.046
Hypertension 77% 86% NS
Diabetes 36% 26% NS
CKD 29% 7% <0.001
Sleep apnea 4% 7% NS
COPD 13% 12% NS
CVA/TIA 23% 11% 0.036
Known CAD 42% 27% 0.059
PAD 23% 15% NS
Home medications
Aspirin 63% 43% 0.013
Dual antiplatelet 21% 8% 0.007
Beta-blocker 46% 31% 0.041
Statin 52% 33% 0.011












23.3 (11.6, 58.5) 69.1 (24.6, 125.5) <0.001
Echocardiographic
EF




UNC Hospitals switched from using troponin T (TnT) to troponin I (TnI) during the
period covered by this study. Echocardiographic ejection fraction (EF) was obtained
within 48 hours of STEMI. STEMI indicates ST -elevation myocardial infarction;
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; TIA, transient ischemic attack; CAD, coronary artery
disease; PAD, peripheral arterial disease; CK-MB, MB fraction of creatine kinase;
NS, not statistically significant.
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whom the timing of the onset of symptoms could be
identified. In the other 4 patients, the symptoms were either
nonspecific (eg, increasing somnolence) or the nursing
documentation was incomplete. By comparison, the median
door to ECG time was 5 (2, 10) minutes in patients who
presented to the emergency department with outpatient
STEMI (P<0.001).
Inpatient STEMI patients who had an ECG performed within
1 hour (n=23) were more likely to have symptoms rather than
a change in clinical status as the event that precipitated the
ECG (61% versus 8%; P<0.001) and had a higher rate of
revascularization (87% versus 56%; P=0.018) compared with
patients who had an ECG performed >1 hour from the event.
There was no significant difference in demographic data
between these 2 groups (data not shown).
Emergent coronary angiography was performed in 71% of
patients with inpatient STEMI. The other patients were
deemed not to be candidates for coronary angiography
because of active or excessive risk of bleeding (n=5), acute
neurological symptoms and/or altered mental status (n=2),
family and/or patient wishes (n=3), and comorbidities (eg,
severe aortic stenosis, pulmonary embolus, ischemic bowel,
CKD; n=3). One patient died awaiting transport to the cardiac
catheterization laboratory.
Emergent PCI was performed in 27 patients (56% of patients
with inpatient STEMI). Reasons for not performing PCI in
patients who underwent coronary angiography included occlu-
sion of a saphenous vein graft (n=1), resolution of ST elevation
with intracoronary bolus of nitroglycerin (n=1), nonobstructive
coronary artery disease (n=1), severe 3-vessel coronary artery
disease with either occlusion of a branch artery or no clear
infarct related artery (n=3), and death prior to performance of
PCI (n=1). The infarct-related artery was the left anterior
descending artery in 12 patients, the right coronary artery in 12
patients, and the left circumflex in 3 patients. Bare-metal stents
were used in 17 patients, drug-eluting stents in 6 patients, and
balloon angioplasty in 4 patients.
The median ECG-to-angiography time was 91 (26, 209)
minutes for inpatient STEMI patients compared with 35 (25,
46) minutes for outpatient STEMI patients (P<0.001; Figure 2
and Table 2). Median ECG to first device activation (FDA) was
129 minutes in inpatient STEMI compared with 60 minutes
for those with outpatient STEMI (P<0.001). There was no
difference in time of arrival in the Cardiac Catheterization
Laboratory to FDA between the 2 groups (Table 2).
Figure 1. Time to obtain ECG in patients with inpatient versus
outpatient STEMI. ECG indicates electrocardiogram; STEMI,
ST-elevation myocardial infarction.
Figure 2. Diagnostic and treatment times in patients with STEMI.
ECG-to-angiography and ECG-to–first device application (FDA) times
for inpatient and outpatient STEMI patients. STEMI indicates
ST-elevation myocardial infarction; ECG, electrocardiogram.
Table 2. Time Required for Coronary Angiography and Revascularization in Patients With Inpatient or Outpatient STEMI Who
Underwent Coronary Angiography
Inpatient STEMI With
Coronary Angiography (n=34) Inpatient STEMI With PCI (n=27) Outpatient STEMI (n=227)
Comparison of Inpatient STEMI
With PCI vs Outpatient STEMI
ECG to angiography 91 (46, 223) 97 (50, 227) 35 (25, 46) P<0.001
Arrival in lab to FDA 26 (15, 49) 23 (17, 30) P=NS
ECG to FDA 129 (65, 250) 60 (47, 76) P<0.001
STEMI indicates ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; ECG, electrocardiogram; FDA, first device activation; NS, not statistically significant.
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In-hospital mortality was 39.6% for inpatient STEMI
patients compared with a rate of 4% for outpatient STEMI
patients (P<0.001). This marked difference in mortality
occurred despite peak cardiac biomarkers being higher in
patients with outpatient STEMIs and postinfarct left ventric-
ular systolic function being the same in the 2 groups
(Table 1). The difference in survival persisted after adjust-
ment for age and sex and after adjustment for age, sex,
history of known coronary artery disease, prior cerebrovas-
cular event, CKD, and use of clopidogrel (Table 3). There was
a marked difference in survival comparing inpatient STEMI
patients who had PCI and outpatient STEMI patients
(Table 3), a difference that persisted after adjusting for
potential confounders.
There were no statistically significant predictors of survival
for inpatient STEMI patients although there were trends that
patients who died were older and more likely to have known
coronary artery disease and diabetes (Table 4). There was a
trend toward survival being higher among patients who
underwent PCI (67.6% versus 42.9%; P=0.11), which was
further strengthened after adjusting for diabetes and known
coronary artery disease (70.3% versus 38.8%; P=0.07). These
data must be interpreted very cautiously because of the small
sample size. The average hospital stay for patients who
survived an inpatient STEMI was 1629 days.
Discussion
The current study highlights significant differences between
patients who develop STEMI while hospitalized for a noncar-
diac condition compared with patients who had onset of STEMI
while outpatients. The former group was older, more likely to
be female, and had a higher rate of CKD and prior cerebro-
vascular events. Fewer inpatient STEMI patients received
coronary angiography or PCI, and the time to reperfusion was
longer than for outpatient STEMI patients. There was a large
amount of variability in time from the onset of MI to
performance of the ECG in hospitalized patients, and ECG-to-
angiography times were significantly longer for inpatient
STEMI than for outpatient STEMI patients. Patients with
inpatient STEMI had a much higher mortality rate, which was
not due to a larger amount of myocardial damage, at least as
assessed by peak cardiac enzymes and post-MI echocardio-
graphic assessment of left ventricular systolic function.
Table 3. Multivariate Analysis of the Difference in Survival Between Inpatient and Outpatient STEMI
Unadjusted Survival Adjusted for Age and Sex
Adjusted for Age, Sex, History of
CAD, Prior CVA, CKD, and
Clopidogrel Usage
Outpatient STEMI 96.1% <0.001 96.8% <0.001 96.9% <0.001
Inpatient STEMI 60.4% 70.5% 63.7%
Adjusted for age, sex, history of CAD
Outpatient STEMI 96.1% <0.001 97.2% <0.001 97.3% <0.001
Inpatient STEMI with PCI 67.6% 76.4% 70.3%
Likelihood analysis was used to identify potential confounders. STEMI indicates ST-elevation myocardial infarction; CAD, coronary artery disease; CVA, cerebrovascular accident; CKD,
chronic kidney disease; PCI, percutaneous coronary intervention.
Table 4. Demographics, Comorbidities, and Treatment Times




Morality (n=19) P Value
Age (y) 66 (58, 75) 73 (66, 80) 0.08
Sex (% female) 45% 58% 0.56
Hypertension 69% 89% 0.16
Diabetes 24% 53% 0.07




Known CAD 31% 58% 0.08
COPD 7% 21% 0.20
Peak CK-MB
(ng/mL)
21.0 (12.9, 60.9) 28.6 (9.9, 55.3) 0.83
Echocardiographic
EF










PCI 62% 47% 0.38
Although there were no statistically significant differences between groups, these results
must be interpreted cautiously, as the small sample size decreases the ability of the
comparison to detect a meaningful difference (a<0.80 for all comparisons). STEMI
indicates ST-elevation myocardial infarction; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; CK-MB, MB fraction of creatine kinase; EF,
ejection fraction; ECG, electrocardiogram; PCI, percutaneous coronary intervention.
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There were 2 major sources of delay in the use of
reperfusion therapy in patients with inpatient STEMI. The first
was the time between the initial clinical event and ECG, which
varied dramatically from a few minutes to more than
48 hours. At least part of this variability was a result of
atypical presentation of STEMI in this patient population. Prior
studies have shown that inpatient acute MI in postoperative
patients is often associated with atypical symptoms and can
be difficult to diagnose.4–6 In our study, the clinical event that
triggered the performance of the index ECG was a change in
clinical status and/or changes observed on telemetry in two
thirds of patients. Patients without symptoms were less likely
to receive an ECG and reperfusion therapy in an expedited
manner compared with patients who verbalized complaints.
For the minority of patients with chest pain (n=7), the median
time between symptom onset to ECG was 10 minutes.
A second major source of delay in reperfusion therapy was
longer and more variable time between ECG and coronary
angiography in patients with inpatient STEMI compared with
patiets with outpatient STEMI. Current guidelines recommend
that patients presenting with an outpatient STEMI have an
ECG within 10 minutes and FDA within 90 minutes. Using an
implied maximum ECG-to-FDA time of 80 minutes as a
performance standard, 81% of outpatient STEMI patients
and 32% of inpatient STEMI patients (P<0.001) had times that
fell within recommendations for optimal care. Although the
current study was not designed to identify the reasons for
these delays, our experience has shown that interpretation of
the ECG is slower than optimum in many of these patients.
This may in part be a result of lack of education, as efforts at
training hospital personnel on the importance of rapid ECG
performance and interpretation in suspected STEMIs have
been concentrated on the emergency department and
cardiology services. Other factors that are likely to contribute
to longer ECG-to-angiography times in these patients are
comorbidities that increase the complexity of evaluating the
risks and benefits of reperfusion therapy and the need for
longer discussions with patients and families regarding
whether to pursue aggressive therapy.
There was no difference in time of arrival in the Cardiac
Catheterization Laboratory to FDA whether a patient had the
onset of STEMI while an inpatient or outpatient. This is in
contrast to the marked differences in the time between MI
onset and coronary angiography between the 2 groups.
Stated another way, once the decision was made to pursue
aggressive measures and the “STEMI system” was activated,
clinical care was similar no matter where the STEMI occurred.
Little has previously been published about outcomes of
inpatient STEMI, but our data are consistent with prior studies
showing high mortality rates for any inpatient MI. Zymslinski
et al4 compared outcomes of inpatient MI with those of
outpatient MI in the prereperfusion era. They found signifi-
cantly higher mortality for inpatient MI (66% versus 22%) and
concluded that it was the result of atypical presentation,
higher comorbidity, and delayed recognition. More recently,
Maynard et al6 reported that in-hospital mortality was much
higher (27.3% versus 8.6%) for 792 patients who experienced
an acute inpatient MI (9.5% who had a STEMI) compared with
6262 patients with acute MI who presented as outpatients to
the Department of Veterans Affairs Health System. Patients
with inpatient MI were older, more likely to have atypical
symptoms, and had higher rates of renal disease, cerebro-
vascular disease, congestive heart failure, diabetes mellitus,
chronic obstructive pulmonary disease, dementia, and cancer
than patients who presented to the VA system with an
outpatient MI.
Inpatient STEMIs are a major health care problem,
suggesting that efforts aimed at improving care of this
patient population would have a large impact. We found that
the incidence of inpatient STEMI in our institution was 3.4 per
10 000 hospital discharges and was associated with an
in-hospital mortality of 40%. According to the Nationwide
Inpatient Sample database of the Healthcare Cost and
Utilization Project, there were 33 million in-patient stays in
2009 in the United States,7 which would project to 11 000 in-
patient STEMIs and 4300 deaths. The problem may actually
be larger than these numbers; although there are very limited
data on the prevalence of acute coronary syndromes in
patients hospitalized for a noncardiac condition, a large,
community-based study found that non-STEMIs occur at a
rate 3 times greater than STEMIs.8
There are several limitations to our study. It is a single-
center, retrospective study with a small cohort. Some patients
with inpatient STEMIs may have been missed in this study
because of either poor coding or sudden death prior to
obtaining an ECG. There are inherent inaccuracies in identi-
fying the onset of myocardial infarction in patients without
symptoms.
Conclusions
The development of a STEMI while hospitalized for a
noncardiac condition is associated with a low use of PCI
and a high mortality rate. A prospective study is needed to
define whether more aggressive use of primary PCI or more
rapid reperfusion therapy results in a decrease in mortality in
these patients, who are older and more often female and have
higher rates of CKD and prior cerebrovascular events than
outpatient STEMI patients. If there is a benefit to decreasing
the time between the onset of coronary ischemia and
revascularization in patients with inpatient STEMI, improve-
ment in outcomes can be achieved by programs aimed at
increasing inpatient STEMI awareness, encouraging early
acquisition of ECG, streamlining ECG interpretation for
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patients not in the emergency department, and establishing
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